AAPL330.49+5.53 (+1.70%) ▲|ABBV260.68-1.04 (-0.40%) ▼|ABT108.84-1.63 (-1.48%) ▼|ACN193.90+6.22 (+3.31%) ▲|ADBE286.31+6.52 (+2.33%) ▲|AMAT435.32-3.14 (-0.72%) ▼|AMD455.80-1.26 (-0.28%) ▼|AMGN442.90+0.06 (+0.01%) ▲|AMT177.25+4.33 (+2.50%) ▲|AMZN258.65+3.67 (+1.44%) ▲|AVGO347.54-19.70 (-5.36%) ▼|AXP330.52+0.54 (+0.16%) ▲|BA207.07-1.80 (-0.86%) ▼|BAC63.11+0.51 (+0.81%) ▲|BKNG198.54-1.06 (-0.53%) ▼|BLK1,116.05+8.97 (+0.81%) ▲|BMY67.55-0.12 (-0.17%) ▼|BNY164.22+2.18 (+1.34%) ▲|BRK-B507.61+2.37 (+0.47%) ▲|C137.73+3.39 (+2.52%) ▲|CAT801.00+8.72 (+1.10%) ▲|CL90.27+0.17 (+0.19%) ▲|CMCSA26.59-0.23 (-0.84%) ▼|COF218.97+2.37 (+1.09%) ▲|COP137.07-0.13 (-0.09%) ▼|COST927.05-1.43 (-0.15%) ▼|CRM264.22+7.29 (+2.84%) ▲|CSCO109.37-0.09 (-0.08%) ▼|CVS97.60+0.37 (+0.38%) ▲|CVX213.02+1.24 (+0.59%) ▲|DE692.91-5.46 (-0.78%) ▼|DHR208.92-0.99 (-0.47%) ▼|DIS107.82-0.16 (-0.15%) ▼|DUK121.56+1.00 (+0.83%) ▲|EMR149.58+0.60 (+0.40%) ▲|FDX320.38+3.84 (+1.21%) ▲|GD362.48-1.59 (-0.44%) ▼|GE332.37+2.87 (+0.87%) ▲|GEV945.25+23.31 (+2.53%) ▲|GILD149.98+0.37 (+0.24%) ▲|GM86.26+1.39 (+1.64%) ▲|GOOG339.54+5.76 (+1.73%) ▲|GOOGL343.03+5.91 (+1.75%) ▲|GS1,036.64+32.22 (+3.21%) ▲|HD317.86+1.68 (+0.53%) ▲|HON206.83+0.76 (+0.37%) ▲|IBM235.25+3.55 (+1.53%) ▲|INTC90.14+0.09 (+0.10%) ▲|INTU349.34+6.40 (+1.87%) ▲|ISRG368.79-3.09 (-0.83%) ▼|JNJ278.07+2.86 (+1.04%) ▲|JPM361.62+5.40 (+1.52%) ▲|KO88.92+0.68 (+0.77%) ▲|LIN483.75-2.10 (-0.43%) ▼|LLY1,152.68-7.41 (-0.64%) ▼|LMT530.78-0.77 (-0.14%) ▼|LOW200.94+1.10 (+0.55%) ▲|LRCX286.57-1.75 (-0.61%) ▼|MA587.11-1.04 (-0.18%) ▼|MCD258.47-2.48 (-0.95%) ▼|MDLZ61.29-1.16 (-1.86%) ▼|MDT92.41+0.23 (+0.24%) ▲|META618.98+26.13 (+4.41%) ▲|MMM167.34-1.41 (-0.84%) ▼|MO69.78+0.22 (+0.32%) ▲|MRK150.44-1.20 (-0.79%) ▼|MS216.99+5.17 (+2.44%) ▲|MSFT512.81+15.99 (+3.22%) ▲|MU945.27-10.81 (-1.13%) ▼|NEE84.11+1.01 (+1.21%) ▲|NFLX82.56-0.17 (-0.21%) ▼|NKE38.21-0.03 (-0.07%) ▼|NOW143.79+7.07 (+5.17%) ▲|NVDA226.98+2.57 (+1.14%) ▲|ORCL152.30+6.55 (+4.49%) ▲|PEP139.66-0.87 (-0.62%) ▼|PFE28.73-0.30 (-1.02%) ▼|PG147.15-0.49 (-0.33%) ▼|PLTR183.42+13.96 (+8.24%) ▲|PM188.56+0.62 (+0.33%) ▲|QCOM169.19+0.15 (+0.09%) ▲|RTX201.25+0.47 (+0.23%) ▲|SBUX106.03-0.69 (-0.65%) ▼|SCHW110.10+1.86 (+1.71%) ▲|SO89.07+0.76 (+0.86%) ▲|SPG211.54+1.34 (+0.64%) ▲|T25.89-0.07 (-0.25%) ▼|TMO611.47+2.93 (+0.48%) ▲|TMUS188.01+0.71 (+0.38%) ▲|TSLA380.40+23.39 (+6.55%) ▲|TXN252.48-2.32 (-0.91%) ▼|UBER75.60-0.86 (-1.12%) ▼|UNH404.94+5.28 (+1.32%) ▲|UNP290.56+0.83 (+0.29%) ▲|UPS102.78-0.23 (-0.22%) ▼|USB63.38+0.61 (+0.96%) ▲|V379.41+1.01 (+0.27%) ▲|VZ50.21-0.01 (-0.02%) ▼|WFC89.61+0.34 (+0.38%) ▲|WMT108.98+2.89 (+2.72%) ▲|XOM164.38+0.23 (+0.14%) ▲|AAPL330.49+5.53 (+1.70%) ▲|ABBV260.68-1.04 (-0.40%) ▼|ABT108.84-1.63 (-1.48%) ▼|ACN193.90+6.22 (+3.31%) ▲|ADBE286.31+6.52 (+2.33%) ▲|AMAT435.32-3.14 (-0.72%) ▼|AMD455.80-1.26 (-0.28%) ▼|AMGN442.90+0.06 (+0.01%) ▲|AMT177.25+4.33 (+2.50%) ▲|AMZN258.65+3.67 (+1.44%) ▲|AVGO347.54-19.70 (-5.36%) ▼|AXP330.52+0.54 (+0.16%) ▲|BA207.07-1.80 (-0.86%) ▼|BAC63.11+0.51 (+0.81%) ▲|BKNG198.54-1.06 (-0.53%) ▼|BLK1,116.05+8.97 (+0.81%) ▲|BMY67.55-0.12 (-0.17%) ▼|BNY164.22+2.18 (+1.34%) ▲|BRK-B507.61+2.37 (+0.47%) ▲|C137.73+3.39 (+2.52%) ▲|CAT801.00+8.72 (+1.10%) ▲|CL90.27+0.17 (+0.19%) ▲|CMCSA26.59-0.23 (-0.84%) ▼|COF218.97+2.37 (+1.09%) ▲|COP137.07-0.13 (-0.09%) ▼|COST927.05-1.43 (-0.15%) ▼|CRM264.22+7.29 (+2.84%) ▲|CSCO109.37-0.09 (-0.08%) ▼|CVS97.60+0.37 (+0.38%) ▲|CVX213.02+1.24 (+0.59%) ▲|DE692.91-5.46 (-0.78%) ▼|DHR208.92-0.99 (-0.47%) ▼|DIS107.82-0.16 (-0.15%) ▼|DUK121.56+1.00 (+0.83%) ▲|EMR149.58+0.60 (+0.40%) ▲|FDX320.38+3.84 (+1.21%) ▲|GD362.48-1.59 (-0.44%) ▼|GE332.37+2.87 (+0.87%) ▲|GEV945.25+23.31 (+2.53%) ▲|GILD149.98+0.37 (+0.24%) ▲|GM86.26+1.39 (+1.64%) ▲|GOOG339.54+5.76 (+1.73%) ▲|GOOGL343.03+5.91 (+1.75%) ▲|GS1,036.64+32.22 (+3.21%) ▲|HD317.86+1.68 (+0.53%) ▲|HON206.83+0.76 (+0.37%) ▲|IBM235.25+3.55 (+1.53%) ▲|INTC90.14+0.09 (+0.10%) ▲|INTU349.34+6.40 (+1.87%) ▲|ISRG368.79-3.09 (-0.83%) ▼|JNJ278.07+2.86 (+1.04%) ▲|JPM361.62+5.40 (+1.52%) ▲|KO88.92+0.68 (+0.77%) ▲|LIN483.75-2.10 (-0.43%) ▼|LLY1,152.68-7.41 (-0.64%) ▼|LMT530.78-0.77 (-0.14%) ▼|LOW200.94+1.10 (+0.55%) ▲|LRCX286.57-1.75 (-0.61%) ▼|MA587.11-1.04 (-0.18%) ▼|MCD258.47-2.48 (-0.95%) ▼|MDLZ61.29-1.16 (-1.86%) ▼|MDT92.41+0.23 (+0.24%) ▲|META618.98+26.13 (+4.41%) ▲|MMM167.34-1.41 (-0.84%) ▼|MO69.78+0.22 (+0.32%) ▲|MRK150.44-1.20 (-0.79%) ▼|MS216.99+5.17 (+2.44%) ▲|MSFT512.81+15.99 (+3.22%) ▲|MU945.27-10.81 (-1.13%) ▼|NEE84.11+1.01 (+1.21%) ▲|NFLX82.56-0.17 (-0.21%) ▼|NKE38.21-0.03 (-0.07%) ▼|NOW143.79+7.07 (+5.17%) ▲|NVDA226.98+2.57 (+1.14%) ▲|ORCL152.30+6.55 (+4.49%) ▲|PEP139.66-0.87 (-0.62%) ▼|PFE28.73-0.30 (-1.02%) ▼|PG147.15-0.49 (-0.33%) ▼|PLTR183.42+13.96 (+8.24%) ▲|PM188.56+0.62 (+0.33%) ▲|QCOM169.19+0.15 (+0.09%) ▲|RTX201.25+0.47 (+0.23%) ▲|SBUX106.03-0.69 (-0.65%) ▼|SCHW110.10+1.86 (+1.71%) ▲|SO89.07+0.76 (+0.86%) ▲|SPG211.54+1.34 (+0.64%) ▲|T25.89-0.07 (-0.25%) ▼|TMO611.47+2.93 (+0.48%) ▲|TMUS188.01+0.71 (+0.38%) ▲|TSLA380.40+23.39 (+6.55%) ▲|TXN252.48-2.32 (-0.91%) ▼|UBER75.60-0.86 (-1.12%) ▼|UNH404.94+5.28 (+1.32%) ▲|UNP290.56+0.83 (+0.29%) ▲|UPS102.78-0.23 (-0.22%) ▼|USB63.38+0.61 (+0.96%) ▲|V379.41+1.01 (+0.27%) ▲|VZ50.21-0.01 (-0.02%) ▼|WFC89.61+0.34 (+0.38%) ▲|WMT108.98+2.89 (+2.72%) ▲|XOM164.38+0.23 (+0.14%) ▲|
25.1 C
New York
Thursday, September 3, 2026

Tag: drugs

newssourceFORcompanyinformationcontent1releasesmarket

Brii Biosciences Announces Licensing Agreement with Joincare Group for Rights to BRII-693 in Greater China

Joincare Group to lead the clinical development and commercialization of BRII-693 in Greater ChinaBrii Biosciences retains ex-Greater China rights to address the global antimicrobial...

Brii Biosciences Announces Licensing Agreement with Joincare Group for Rights to BRII-693 in Greater China

Joincare Group to lead the clinical development and commercialization of BRII-693 in Greater ChinaBrii Biosciences retains ex-Greater China rights to address the global antimicrobial...

Remote Pharmacy Releases 2025 Availability Update on GLP-1 Weight Loss Solutions and Consumer Interest in Semaglutide & Tirzepatide

In this 2025 availability update, Remote Pharmacy highlights the expanded access to non-branded GLP-1-based weight management options, including semaglutide and tirzepatide compounds. The release explores the evolving role of compounded therapeutics, shifts in consumer behavior toward remote prescribing, and how new formulations align with the growing interest in safe, physician-directed care for weight management. 
In this 2025 availability update, Remote Pharmacy highlights the expanded access to non-branded GLP-1-based weight management options, including semaglutide and tirzepatide compounds. The release explores the evolving role of compounded therapeutics, shifts in consumer behavior toward remote prescribing, and how new formulations align with the growing interest in safe, physician-directed care for weight management.

High-Potency OTC NMN Supplement from Wonderfeel Launches Amid Surging Demand for Clean NAD+ Support Solutions

Wonderfeel’s 2025 Youngr™ update features a 900mg stabilized NMN dose with antioxidant co-factors, formulated to align with consumer interest in bioavailable, non-synthetic NAD+ wellness support. 
Wonderfeel’s 2025 Youngr™ update features a 900mg stabilized NMN dose with antioxidant co-factors, formulated to align with consumer interest in bioavailable, non-synthetic NAD+ wellness support.

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, July 03, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on July 1, 2025 (the “Grant Date”), ORIC granted a total of 9,000 non-qualified stock options and 1,600 restricted stock units to one new non-executive employee who began their employment with ORIC in June 2025.

Robotic Surgery Market 2025 Trends: Advanced AI Systems, Telesurgery and $400M Investments Power Global Expansion

The global robotic surgery market size is calculated at USD 13.79 billion in 2025 and is expected to reach around USD 54.66 billion by 2034, growing at a CAGR of 16.54% for the forecasted period. 
The global robotic surgery market size is calculated at USD 13.79 billion in 2025 and is expected to reach around USD 54.66 billion by 2034, growing at a CAGR of 16.54% for the forecasted period.

Zhengye Biotechnology Holding Limited Announces Fiscal Year 2024 Financial Results

JILIN, China, July 3, 2025 /PRNewswire/ -- Zhengye Biotechnology Holding Limited (Nasdaq: ZYBT) (the "Company" or "Zhengye"), a veterinary vaccine manufacturer that encompasses research, development, manufacturing, and...

Fangzhou Tops China’s App Store Chart for Healthcare Apps

GUANGZHOU, China, July 3, 2025 /PRNewswire/ -- Fangzhou Inc. ("Fangzhou" or the "Company") (06086.HK), a leader in Internet healthcare solutions, earned the top spot in...

Jacobio’s IND for Phase I/II Clinical Trial of BET Inhibitor JAB-8263 in Autoimmune Diseases has been Accepted

BEIJING, SHANGHAI and BOSTON, July 2, 2025 /PRNewswire/ -- Jacobio Pharma (1167.HK) announced that it has submitted the Phase I/II Investigational New Drug (IND)...

Hims & Hers Health, Inc. (HIMS) Faces Securities Class Actions After Novo Nordisk Cancels Partnership Over “Deceptive” Marketing of Wegovy– Hagens Berman

HIMS Investors with Losses Encouraged to Contact Hagens Berman 
HIMS Investors with Losses Encouraged to Contact Hagens Berman

Sleep Apnea Market to Accelerate Substantially at a CAGR of 20% During the Study Period (2020-2034) | DelveInsight

The sleep apnea market growth is driven by rising awareness, technological advancements, and demand for personalized care. Companies innovate therapies and solutions for better...

OXLUMO® (lumasiran injection) Now Reimbursed in Canada For the Treatment of Primary Hyperoxaluria Type 1 (PH1) in Pediatric and Adult Patients

OXLUMO has been shown to significantly reduce urinary oxalate, which drives the progression of PH1 Disease1 MISSISSAUGA, ON, July 2, 2025 /CNW/ - Alnylam Canada ULC...

I-Mab Presents Positive Givastomig Phase 1b Dose Escalation Data in Combination with Immunochemotherapy in Patients with 1L Gastric Cancers at ESMO GI 2025

Data show confirmed ORR of 83% (10/12) at doses selected for ongoing expansion study

Lynozyfic™ (linvoseltamab-gcpt) Receives FDA Accelerated Approval for Treatment of Relapsed or Refractory Multiple Myeloma

Lynozyfic is a bispecific antibody directing T cells to kill multiple myeloma cancer cells; multiple myeloma is the second most common blood cancer 

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsDrugs

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers